TG Therapeutics (NASDAQ:TGTX - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 4th. Analysts expect the company to announce earnings of $0.27 per share and revenue of $147.76 million for the quarter.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm's revenue was up 90.4% compared to the same quarter last year. During the same period last year, the business earned ($0.07) EPS. On average, analysts expect TG Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.
TG Therapeutics Stock Down 1.4%
NASDAQ:TGTX traded down $0.48 during mid-day trading on Friday, hitting $35.02. The stock had a trading volume of 2,316,464 shares, compared to its average volume of 1,512,933. The stock has a 50-day simple moving average of $36.83 and a two-hundred day simple moving average of $36.01. The company has a market capitalization of $5.56 billion, a PE ratio of 145.92 and a beta of 1.95. TG Therapeutics has a twelve month low of $16.65 and a twelve month high of $46.48. The company has a current ratio of 4.02, a quick ratio of 3.04 and a debt-to-equity ratio of 1.03.
Analyst Ratings Changes
Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $43.80.
Read Our Latest Research Report on TG Therapeutics
Insiders Place Their Bets
In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the sale, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.64% of the company's stock.
Institutional Trading of TG Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. raised its holdings in TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company's stock worth $75,683,000 after purchasing an additional 345,059 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TG Therapeutics by 5.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company's stock worth $11,319,000 after purchasing an additional 14,689 shares in the last quarter. Royal Bank of Canada raised its holdings in TG Therapeutics by 16.4% during the first quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company's stock worth $2,985,000 after purchasing an additional 10,660 shares in the last quarter. Finally, NewEdge Advisors LLC raised its holdings in TG Therapeutics by 9.6% during the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company's stock worth $299,000 after purchasing an additional 665 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.
TG Therapeutics Company Profile
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access